Scarica l'app Stockscreener
2.39
2.45%
-0.06
Dopo l'orario di chiusura:
2.40
0.010
+0.42%
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World
Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World
AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World
HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st
Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2025 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm - TipRanks
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% By Investing.com - Investing.com Nigeria
AQST Price Target Reduced by Piper Sandler | AQST Stock News - GuruFocus
Aquestive (AQST) Reports Lower Q1 Revenue, Focuses on Anaphylm L - GuruFocus
Aquestive Therapeutics (AQST) Anticipates FDA Milestone for Anap - GuruFocus
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% - Investing.com
Aquestive Therapeutics Inc Reports Q1 2025 EPS of -$0.24, Missin - GuruFocus
Aquestive Therapeutics: Q1 Earnings Snapshot - The Washington Post
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 Result - GuruFocus
Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials - Investing.com Australia
Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c) - TipRanks
Aquestive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aquestive Therapeutics Submits NDA for Anaphylm - TipRanks
Aquestive Therapeutics, Inc. SEC 10-Q Report - TradingView
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday - Defense World
Aquestive Therapeutics (AQST) Q1 Earnings Preview: Expectations and Revisions - GuruFocus
Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Raymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Wells Fargo & Company MN - Defense World
Aquestive Therapeutics at Citizens JMP: Strategic Moves in Allergy Treatment - Investing.com Australia
Quarterly Metrics: Quick and Current Ratios for Aquestive Therapeutics Inc (AQST) - DWinneX
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference - The Manila Times
Aquestive Therapeutics CEO Fireside Chat: Key Updates Coming at Citizens Life Sciences Conference - Stock Titan
Renaissance Technologies LLC Boosts Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential - Seeking Alpha
JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Inc (AQST) deserves deeper analysis - uspostnews.com
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics Inc (AQST) receives an Overweight rating from Cantor Fitzgerald - knoxdaily.com
Aquestive Therapeutics Inc’s Market Journey: Closing Weak at 2.83, Down -1.39 - DWinneX
Anaphylaxis Treatment Market Size in 7MM is expected to grow at - openPR.com
1.37%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):